Belluscura (LSE:BELL) Common Stock: £1.73 Mil (As of Jun. 2024)


What is Belluscura Common Stock?

Belluscura LSE:BELL Common Stock is £1.73 Mil as of Jun. 2024.

Belluscura's quarterly common stock increased from Jun. 2023 (£1.43 Mil) to Dec. 2023 (£1.46 Mil) and increased from Dec. 2023 (£1.46 Mil) to Jun. 2024 (£1.73 Mil).

Belluscura's annual common stock increased from Dec. 2021 (£1.16 Mil) to Dec. 2022 (£1.37 Mil) and increased from Dec. 2022 (£1.37 Mil) to Dec. 2023 (£1.46 Mil).

Belluscura Common Stock Historical Data

* Premium members only.

The historical data trend for Belluscura's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belluscura Common Stock Chart

Belluscura Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial 0.49 0.61 1.16 1.37 1.46

Belluscura Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.33 1.37 1.43 1.46 1.73

Belluscura Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of £1.73 Mil mean?
Belluscura (LSE:BELL) has a Common Stock of £1.73 Mil as of Jun. 2024. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Belluscura and its competitors.
Is Belluscura's Common Stock too high?
Belluscura's current Common Stock is £1.73 Mil.
How does Belluscura's Common Stock compare to ABT and BSX?
Belluscura's Common Stock of £1.73 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Medical Devices & Instruments company?
A good Common Stock depends on the Medical Devices & Instruments industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Belluscura and its competitors. Belluscura's current Common Stock is £1.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belluscura stock overvalued right now?
Belluscura (LSE:BELL) has a current Common Stock of £1.73 Mil. The current Common Stock is £1.73 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Belluscura (LSE:BELL), the current Common Stock is £1.73 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belluscura Business Description

Address 15 Fetter Lane, Holborn, London, GBR, EC4A 1BW
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company has only one operating segment being the sale of oxygen concentrators in the United States. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.